

Mainstay Medical gibt Halbjahresergebnis für 2018 und Geschäftsausblick bekannt

- Studie ReActiv8-B plangemäß – volle Datenergebnisse gegen Ende 2018 erwartet
- Finanzierungsrunde in Höhe von 37,5 Millionen US-Dollar (30 Millionen Euro) für die Komplettierung der ReActiv8-B-Studie und die Ausweitung des Vertriebs in Europa erfolgreich abgeschlossen
- Barmittelbestand 29,7 Millionen US-Dollar zum Stichtag 30. Juni 2018

Dublin – Irland, 21. September 2018 – Mainstay Medical International plc („Mainstay“, oder das „Unternehmen“, Euronext Paris: MSTY.PA und Euronext Dublin: MSTY.IE) gibt die Vorlage der Ergebnisse für das per 30. Juni abgeschlossene erste Halbjahr 2018 bekannt und berichtet über die neueste Geschäftsentwicklung. Das Medizintechnik-Unternehmen Mainstay vertreibt ReActiv8®, ein implantierbares wiederherstellendes Neurostimulationssystem, das zur Behandlung von einschränkenden chronischen Kreuzschmerzen (Chronic Low Back Pain, CLBP) ausgelegt ist.

Jason Hannon, der Vorstandsvorsitzende von Mainstay, sagte: *“Die jüngste Periode hat gezeigt, dass wir bedeutende Fortschritte über die gesamte Breite des Geschäftes gemacht haben. Wir haben den Abschluss aller Implantationen in der Studie ReActiv8-B bekannt gegeben und bleiben auf gutem Weg, die vollständigen Daten Ende 2018 zur Verfügung zu haben. Das ist ein bedeutender Schritt, unsere Bemühungen zu stärken, ReActiv8 den Patienten in den USA zur Verfügung zu stellen.*

“Wir konzentrieren uns darauf, schnelle Fortschritte in Deutschland zu erzielen, in unserem ersten kommerziellen Markt. Von März an haben wir unsere Vertriebsstrategie weiterentwickelt, unser Vertriebsteam neu aufgestellt, uns auf die Fortbildung der neuen und vorhandenen Teammitglieder fokussiert und unsere Ansprache potentieller implantierender Ärzte verstärkt. Wir haben zudem einen neuen Geschäftsführer berufen, der das Wachstum unseres Geschäftes in Deutschland, den Aufbau von Beziehungen zu wichtigen Implantateuren sowie die Erweiterung unseres Teams mit erfahrenen Vertriebsmitarbeitern verantwortet, die ReActiv8 schnell im Markt verbreiten können.

In den vergangenen Monaten haben wir ermutigende Hinweise gesehen, dass diese Initiativen Wirkung zeigen. Wichtig ist auch, dass wir bei unserem Ziel, bis Jahresende zehn oder mehr ärztliche Partner zu gewinnen, die mehrere Implantationen vorgenommen haben, auf Kurs bleiben. Wir glauben, dass uns dieser Schwung für eine bedeutsamere geschäftliche Expansion im Jahr 2019 gut aufstellt, während mehr Kunden die Therapie annehmen und sicherer dabei werden, die richtigen Patienten auszuwählen. ”

Business-Update

- Während der ersten Hälfte des Jahres 2018 machte Mainstays unter einer Investigational Device Exemption (IDE) aufgelegte klinische Pivotalstudie ReActiv8-B weiter entscheidende Fortschritte. Sie soll Daten gewinnen, die Teil eines Pre-Market-Approval-Antrags (PMAA) bei der US Food and Drug Administration (FDA) werden sollen. Dies ist ein entscheidender Schritt für den Vertrieb von ReActiv8 in den USA. Der Abschluss aller Implantationen wurde zu Beginn des dritten Quartals 2018 gemeldet. Insgesamt 204 Patienten wurden im Rahmen der Studie implantiert, was das hohe Interesse widerspiegelt, an der Studie teilzunehmen. Der Abschluss der Implantationen im Rahmen der Studie

bedeutet, dass das Unternehmen auf einem guten Weg ist, die vollständigen Daten gegen Ende 2018 bekannt zu geben.

- In Deutschland, Mainstays anfänglichem Europäischen Markt, wurde das Vertriebsteam repositioniert, damit es bei seiner Arbeit besser auf wichtige ärztliche Zielkunden fokussieren kann. Die Vertriebsmaßnahmen gemäß dieser Strategie begannen im März 2018 nach Abschluss der im Februar 2018 angekündigten Finanzierungsrunde, und greifen immer mehr. Die Implantationsrate und die Zahl der neuen implantierenden Häuser sind im Juli und August 2018 gegenüber den ersten sechs Monaten des Jahres stark gestiegen.
- Wolfgang Frisch wurde am 20. Juni 2018 zum VP und Geschäftsführer für Deutschland berufen. Er hat über 30 Jahre Erfahrung in der Medizintechnikbranche und wird dazu beitragen, die Vertriebsstrategie weiter voranzutreiben, mit Fokus auf die Übernahme der Therapie in einer ausgewählten Zahl von Wirbelsäulenzentren mit hohem Patientenaufkommen zu erreichen.
- Matthew Onaitis wurde per 20. August 2018 als Chief Financial Officer berufen. Er bringt mehr als 20 Jahre Erfahrung in der Arbeit bei dynamischen Gesundheitsunternehmen mit und hat tiefgehende Kenntnisse der Finanzierung von innovativen Wachstumsunternehmen wie Mainstay.

Finanz-Update

- Am 15. Februar 2018 gab das Unternehmen den Abschluss einer Finanzierungsrunde mit einem Volumen von 30,1 Million Euro (rund 37,5 Millionen US-Dollar) bekannt, die durch die Platzierung von 2.151.332 neuen Stammaktien an neue und alte Aktionäre erfolgte. Die Finanzmittel werden für den Abschluss der klinischen Studie ReActiv8-B, den Fortgang des anfänglichen Vertriebs in Deutschland und anderen Märkten und für Investitionen in frühe Vertriebsaktivitäten zur Vorbereitung des Marktstarts in den USA verwendet.
- Die Erlöse in der per 30. Juni 2018 abgeschlossenen Sechsmonatsperiode beliefen sich auf 0,4 Millionen US-Dollar (0,3 Millionen US-Dollar im ersten Halbjahr 2017).
- Die betrieblichen Aufwendungen lagen bei 15,8 Millionen US-Dollar (12,3 Millionen US-Dollar im ersten Halbjahr 2017). Dieser Anstieg wurde vor allem von den Kosten der Studie ReActiv8-B und der Vertriebsanstrengungen getrieben.
- Der Barmittelbestand betrug 29,7 Millionen US-Dollar zum Stichtag 30. Juni 2018 (10 Millionen US-Dollar per 31. Dezember 2017).

Telefonkonferenz für Investoren

Der Vorstandsvorsitzende Jason Hannon und der Chief Executive Officer Matthew Onaitis werden am 21. September 2018 um 14:00 MEZ eine Telefonkonferenz einschließlich Frage- und Antwortrunde für Analysten und Investoren abhalten. Die Telefonkonferenz wird in Englischer Sprache ablaufen. Ein Mitschnitt wird 30 Tage lang zur Verfügung stehen. Die Einwahlnummern der Telefonkonferenz sind wie folgt:

Europa: +44 333 300 0804

Irland: +353 1 431 1252

Frankreich: +33 170750711

Deutschland: +49 6913803430

USA: +1 6319131422

Teilnehmer-PIN: 87237611#

– Ende –

Über Mainstay

Mainstay ist ein Medizintechnik-Unternehmen mit dem Ziel, das innovative implantierbare Neurostimulationssystem ReActiv8 für Menschen mit einschränkenden chronischen Kreuzschmerzen (Chronic Low Back Pain, CLBP) zu vertreiben. Das Unternehmen hat seinen Hauptsitz in Dublin, Irland. Es ist mit Tochtergesellschaften in Irland, in den USA, in Australien, und in Deutschland tätig. Seine Aktien sind zum Handel an der Börse Euronext Paris (MSTY.PA) und am ESM der Euronext Dublin (MSTY.IE) zugelassen.

Über chronische Kreuzschmerzen

Eine der anerkannten Ursachen von chronischen Kreuzschmerzen (Chronic Low Back Pain, CLBP) ist die gestörte Kontrolle des Nervensystems über die Muskeln, die für die dynamische Stabilisierung der Wirbelsäule im unteren Rücken zuständig sind. Eine instabile Wirbelsäule kann zu Rückenschmerzen führen. ReActiv8 ist so konstruiert, dass es diejenigen Nerven elektrisch stimuliert, die für die Kontraktion dieser Muskeln zuständig sind. Dadurch hilft es, die Kontrolle über die Muskeln wieder herzustellen und die dynamische Stabilisierung der Wirbelsäule zu verbessern, was dem Körper eine Genesung von den chronischen Kreuzschmerzen erlaubt.

Menschen mit chronischen Kreuzschmerzen haben üblicherweise eine stark reduzierte Lebensqualität und weisen erhöhte Werte bei Schmerz, Einschränkungen, Depressionen, Angstzuständen und Schlafstörungen auf. Ihre Schmerzen und Einschränkungen können trotz bester verfügbarer medizinischer Behandlung fortbestehen. Nur ein kleiner Teil der Fälle lässt sich auf einen pathologischen Befund oder einen anatomischen Defekt zurückführen, der mit einem wirbelsäulen chirurgischen Eingriff korrigierbar wäre. Die Betroffenen sind durch die Beschwerden in ihrer Arbeitsfähigkeit und Alltagstauglichkeit stark eingeschränkt. Die Verluste an Arbeitstagen, Hilfeleistungen bei Schwerbehinderung und Inanspruchnahme medizinischer Leistungen ist eine erhebliche Belastung für den Einzelnen, seine Familie, die Wirtschaft, die öffentliche Verwaltung und für die Allgemeinheit.

Weitere Einzelheiten finden sich unter www.mainstay-medical.com

ACHTUNG – in den USA ist ReActiv8 durch Bundesgesetze auf den Einsatz in der Forschung beschränkt.

PR- und IR-Anfragen:

Consilium Strategic Communications (Internationale Strategische Kommunikation, Wirtschafts- und Fachmedien)

Chris Gardner, Jessica Hodgson, Nicholas Brown

Tel: +44 203 709 5700 / +44 7921 697 654

Email: mainstaymedical@consilium-comms.com

FTI Consulting (für Irland)

Jonathan Neilan

Tel: +353 1 765 0886

Email: jonathan.neilan@fticonsulting.com

NewCap (für Frankreich)

Julie Coulot

Tél. : +33 1 44 71 20 40

Email: jcoulot@newcap.fr

AndreasBohne.Com/Kötting Consulting (für Deutschland)

Andreas Bohne

Tel : +49 2102 1485368

Email : abo@andreasbohne.com

Wilhelm Kötting

Tel: +49 69 75913293

Email: wkotting@gmail.com

Investor Relations:

LifeSci Advisors, LLC

Brian Ritchie

Tel: +1 (212) 915-2578

Email: britchie@lifesciadvisors.com

ESM Advisers:

Davy

Fergal Meegan oder Barry Murphy

Tel: +353 1 679 6363

Email: fergal.meegan@davy.ie or barry.murphy2@davy.ie

In die Zukunft gerichtete Aussagen

Diese Mitteilung enthält Aussagen, die in die Zukunft gerichtet sind oder so verstanden werden könnten. Diese in die Zukunft gerichteten Aussagen sind kenntlich durch Formulierungen, die in die Zukunft weisen, einschließlich Ausdrücken wie "antizipiert", "glaubt", "schätzt", "erwartet", "beabsichtigt", "mag", "plant", "projektiert", "sollte", "will" oder "untersucht", oder jeweils durch deren negative oder andere Varianten, oder durch vergleichbare Formulierungen, oder durch Darlegungen von Strategie, Plänen, Planzielen, Zielsetzungen, künftigen Ereignissen oder Absichten. Diese in die Zukunft gerichteten Aussagen schließen alles jenseits der historischen Fakten ein. Sie sind Teil dieser Mitteilung und schließen Absichten des Unternehmens, Überzeugungen oder gegenwärtige Erwartungen unter anderem betreffend die Erlöse des Unternehmens, seine finanzielle Lage, Vorstellungen, Finanzstrategien, Erwartungen an Produktentwurf oder Entwicklung, regulatorische Anträge und Zulassungen, Erstattungsregelungen, Kosten für Vermarktung und Marktdurchdringung sowie andere kommerzielle Leistungen ein, sie sind aber darauf nicht beschränkt.

Es liegt in der Eigenart von in die Zukunft gerichteten Aussagen, dass sie Risiken und Unwägbarkeiten einschließen, weil sie sich auf künftige Ereignisse und Umstände beziehen. In die Zukunft gerichtete Aussagen sind keine Garantien künftiger Leistungsfähigkeit, und die tatsächlichen Ergebnisse der Tätigkeit des Unternehmens, die Entwicklung seines Hauptproduktes, der Märkte und der Branche in der das Unternehmen tätig ist, können wesentlich von jenen abweichen, die durch in die Zukunft gerichtete Aussagen in dieser Mitteilung beschrieben oder angedeutet werden. Sogar wenn die Ergebnisse der Tätigkeit des Unternehmens, seine finanzielle Lage und sein Wachstum, sowie die Entwicklung seines Hauptproduktes, der Märkte und der Branche, in der es tätig ist, mit den in dieser Mitteilung enthaltenen in die Zukunft gerichteten Aussagen überein stimmen, sind diese Ergebnisse oder Entwicklungen nicht unbedingt ein Hinweis auf Ergebnisse oder Entwicklungen in Folgeperioden. Zahlreiche Faktoren könnten dafür sorgen, dass Ergebnisse und Entwicklungen des Unternehmens erheblich von jenen abweichen, die ausdrücklich oder implizit in den in die Zukunft gerichteten Aussagen genannt sind. Das schließt uneingeschränkt den erfolgreichen Marktstart und die Vermarktung von ReActiv8, den Fortschritt und Erfolg der klinischen Studie ReActiv8-B, allgemeine wirtschaftliche und geschäftliche Umstände, Bedingungen am weltweiten Medizintechnik-Markt, Branchentrends, Wettbewerb, gesetzliche oder regulatorische Veränderungen, steuerliche Veränderungen, die Verfügbarkeit und Kosten von Kapital, die zur Auflage und zum Abschluss klinischer Studien benötigte Zeit, die zur Erlangung regulatorischer Zulassungen erforderliche Zeit und Prozesse, Wechselkursveränderungen, Veränderungen der Geschäftsstrategie sowie politische und wirtschaftliche Unwägbarkeiten ein. Die hier genannten in die Zukunft gerichteten Aussagen sind nur aussagekräftig zum Zeitpunkt dieser Mitteilung.

Mainstay Medical International plc and its subsidiaries

Half Year Report comprising Interim Management Report and condensed consolidated Financial Statements for the half year ended 30 June 2018

Mainstay Medical International plc
Table of contents

Corporate and shareholder information	3
Interim Management Report	4
Director's Responsibilities Statement	8
Condensed consolidated statement of profit or loss and other comprehensive income	9
Condensed consolidated statement of financial position	10
Condensed consolidated statement of changes in shareholders' equity	11
Condensed consolidated statement of cash flows	12
Notes to the condensed consolidated Financial Statements	13

Forward looking statements

This report includes statements that are, or may be deemed to be, forward looking statements. These forward looking statements can be identified by the use of forward looking terminology, including the terms "anticipates", "believes", "estimates", "expects", "intends", "may", "plans", "projects", "should", "will", or "explore" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. These forward looking statements include all matters that are not historical facts. They appear throughout this report and include, but are not limited to, statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, including commercial performance, financial position, prospects, financing strategies, expectations for product design and development, regulatory applications and approvals, commercialization plans, reimbursement arrangements, costs of sales and market penetration.

By their nature, forward looking statements involve risk and uncertainty because they relate to future events and circumstances. Forward looking statements are not guarantees of future performance and the actual results of the Company's operations, including commercial performance, and the development of its main product, the markets and the industry in which the Company operates, may differ materially from those described in, or suggested by, the forward looking statements contained in this report. In addition, even if the Company's results of operations, commercial performance, financial position and growth, and the development of its main product and the markets and the industry in which the Company operates, are consistent with the forward looking statements contained in this report, those results or developments may not be indicative of results or developments in subsequent periods. A number of factors could cause results and developments of the Company to differ materially from those expressed or implied by the forward looking statements including, without limitation, the successful launch and commercialization of ReActiv8, the progress and success of the ReActiv8-B Clinical Trial, general economic and business conditions, global medical device market conditions, industry trends, competition, changes in law or regulation, changes in taxation regimes, the availability and cost of capital, the time required to commence and complete clinical trials, the time and process required to obtain regulatory approvals, currency fluctuations, changes in its business strategy, and political and economic uncertainty. The forward-looking statements herein speak only at the date of this report.

Mainstay Medical International plc
Corporate and shareholder information

Directors	Oern Stuge MD, Independent Non-Executive Chairman Jason Hannon, Chief Executive Officer and Executive Director David Brabazon, Independent Non-Executive Director Greg Garfield, Non-Executive Director Nael Karim Kassar, Non-Executive Director Antoine Papiernik, Non-Executive Director James Reinstein, Independent Non-Executive Director Manus Rogan PhD, Non-Executive Director Dan Sachs MD, Non-Executive Director
Secretary	Tom Maher
Registered office	Clonmel House Forster Way Swords, K67F2K3 County Dublin, Ireland
Registered number	539688
Website	www.mainstay-medical.com
ISIN / Symbol	IE00BJYS1G50 / MSTY.PA (Paris) and MSTY.IE
Solicitors/ Lawyers	McCann FitzGerald Riverside One Sir John Rogerson's Quay Dublin 2, Ireland Latham Watkins 885 3 rd Avenue, NY 10022, USA
Independent Auditor	KPMG Chartered Accountants 1 Stokes Place St Stephen's Green Dublin 2, Ireland
Principal Bankers	HSBC Bank of Ireland
ESM Adviser and Broker	J&E Davy Davy House 49 Dawson Street Dublin 2, Ireland
Registrar	Computershare Investor Services (Ireland) Limited Heron House Corrig Road Sandyford Industrial Estate Dublin 18, Ireland
Paying Agent (in France)	Caceis Corporate Trust 1/3, Place Valhubert 75013 Paris, France

Mainstay Medical International plc Interim Management Report

The Board of Directors is pleased to report on the progress of Mainstay Medical International plc (Mainstay or the Company) and present the Half Year Report for the half year ended 30 June 2018 of the Company and its subsidiaries (the Group or we).

Principal activities

Mainstay is a medical device company focused on commercializing ReActiv8[®], an implantable restorative neurostimulation system designed to treat an underlying cause of disabling Chronic Low Back Pain (CLBP). ReActiv8 is designed to electrically stimulate the nerves responsible for contracting a muscle which stabilizes the lumbar spine. Activation of this muscle to restore functional stability has been shown to facilitate recovery from CLBP. Mainstay received CE Marking for ReActiv8 based on positive results from the ReActiv8-A Clinical Trial which demonstrated a statistically significant and lasting improvement in pain, disability and quality of life in people with disabling CLBP.

The Company is incorporated in Ireland as a public limited company. The Company's ordinary shares are listed on the ESM of Euronext Dublin and Euronext Paris.

As at 30 June 2018, the Company and its operating subsidiaries Mainstay Medical Limited, MML US, Inc., Mainstay Medical (Australia) Pty Limited, Mainstay Medical Distribution Limited, Mainstay Medical B.V. and Mainstay Medical GmbH form the Mainstay Medical Group.

Business review

ReActiv8-B Clinical Trial – The ReActiv8-B Clinical Trial (the Trial) is an international, multi-center, prospective, randomized, sham-controlled, triple blinded trial with one-way crossover, conducted under an Investigational Device Exemption (IDE) from the US Food and Drug Administration (FDA).

The Trial is intended to gather data in support of an application for pre-market approval (PMA) from the FDA, a key step towards the commercialization of ReActiv8 in the US. Information about the trial can be found at <https://clinicaltrials.gov/ct2/show/study/NCT02577354>.

The primary efficacy endpoint of the Trial is a comparison of responder rates between the treatment and control arms. The Trial will be considered a success if there is a statistically significant difference in responder rates between the treatment and control arms. The Trial, if successful, will provide Level 1 Evidence of efficacy of ReActiv8, which may be used to support applications for reimbursement in the US. Data from the Trial will also be used to support market development activities worldwide.

In December 2017, the independent Data Monitoring Committee (DMC) completed the pre-planned interim analysis of the Trial, which was based on data from the first 58 patients in the pivotal cohort to complete the primary endpoint. The DMC recommended continuation of the Trial with a definitive size of 168 evaluable patients. The DMC also reported that they had observed no safety concerns in the Trial.

During the first half of 2018, significant further progress was made to advance the Trial. In July 2018, we announced completion of all implants in the Trial. Because of enrollment momentum at our clinical sites at the time of and following the interim review of the data, and reflecting the strength of interest in the Trial, a total of 204 patients were implanted. The completion of implants in the Trial means the Company remains on track to announce full data towards the end of 2018.

Commercialization – In Germany, Mainstay's initial European market, the commercial team was repositioned in order to better focus efforts on key physician targets. Commercialization efforts in line with this strategy began in earnest in March 2018, post our financing announced in February 2018, and are gaining traction. Our strategy is to focus on adoption in a select number of high volume spine care centres. The rates of implants and new implanting sites have increased sharply in July and August 2018 as compared to the first six months of the year.

We have continued to add to our investment in commercial infrastructure to expand commercialization in Europe, and in preparation to enter other markets in the future. We will also increase our investment in the training of physicians; the education of referring physicians regarding the potential of ReActiv8; and the collection and dissemination of clinical data regarding use of ReActiv8.

Funding – On 15 February 2018, we announced the completion of a €30.1 million financing (approximately \$37.5 million) through a placement of 2,151,332 new ordinary shares to new and existing shareholders. On 4 May 2018, we announced the publication of a prospectus (the Prospectus) in connection with the Placement. The funds are being used to complete the ReActiv8-B Clinical Trial, advance the initial commercialization of ReActiv8 in Germany and other markets and invest in early commercial activities in preparation for launch in the US. The Prospectus comprises a Summary Document, a Securities Note and a Registration Document. These documents are available on our website (www.mainstay-medical.com).

ReActiv8-A Post Market Clinical Follow up (PMCF) Study – The ReActiv8-A Clinical Trial was an international, multi-center, prospective, single arm clinical trial of ReActiv8 that formed the basis of our CE mark for ReActiv8.

Following CE marking approval, a range of activities is required for post market clinical follow up to gather additional data on the long-term performance and safety of ReActiv8. The ReActiv8–A PMCF Study is a continuation of the ReActiv8-A Clinical Trial (but using CE Marked ReActiv8). All subjects enrolled in the ReActiv8–A Clinical Trial in Belgium and the UK are being converted to the ReActiv8-A PMCF Study. Physicians commenced with these implants in late 2017, and the full 40 implants are expected to be completed by the end of 2018.

ReActiv8-C Registry – In addition to the ReActiv8-A PMCF Study, the Company is maintaining the ReActiv8-C Registry, an international, multi-centre data collection registry. All centres that use the product commercially are invited to participate in the Registry program. All patients who are implanted with ReActiv8 at the centres participating in the Registry will be invited to enrol in the Registry until the target enrolment numbers have been reached. The purpose of the Registry is to gather additional summary data on long term performance of ReActiv8 in at least 50 patients.

Financial review

Income Statement – Revenue during the six-month period ending 30 June 2018 was \$0.36 million (\$0.25 million during the same period in 2017). Revenue was generated from sales of ReActiv8 systems to customers in Germany and Ireland.

Operating expenses related to on-going activities were \$15.8 million during the half year ended 30 June 2018 (same period in 2017: \$12.3 million). On-going activities during the financial year included research and development, clinical and regulatory activities, selling, general and administrative activities.

Research and development expenses were \$2 million during the six-month period ended 30 June 2018, which is consistent with expenditure of \$2 million during the same period in 2017. Expenditure during the 2018 period included the salaries of engineers, technicians, and quality and regulatory specialists; the cost of outsourced development and manufacturing activities; biocompatibility and pre-clinical studies; and quality costs including the maintenance of our quality system.

Clinical and regulatory expenses were \$7.2 million during the six-month period ended 30 June 2018 and increased by \$2 million from \$5.2 million during the same period in 2017. This is primarily driven by increased direct trial costs, consulting, training and travel costs relating to activities for the Trial, which has sites in the U.S., Australia and Europe.

Our selling, general and administrative expenses were \$6.6 million during the six-month period ended 30 June 2018, and \$5.1 million during the same period in 2017. The increase of \$1.5 million is primarily driven by commercialization and the related increase in our direct sales force (impacting recruitment fees, payroll, travel and training costs), as well as marketing, reimbursement consulting and market research costs. This increase is also impacted by a non-cash expense for share options granted. Selling, general and administrative expenses are expected to increase in future years, as we increase our direct sales team to drive activities to promote growth.

Statement of financial position – Total assets of the Group at 30 June 2018 were \$33.6 million (31 December 2017: \$13.3 million). Cash on hand at 30 June 2018 was \$29.7 million (31 December 2017: \$10 million). Cash used in operating activities was \$14.8 million during the period (30 June 2017: \$11.4 million) and is reflective of our increased operating expenses.

The Group's debt facility provided by IPF Partners was entered into on 24 August 2015 for up to \$15 million. The Group had drawn down \$4.5 million on 9 September 2015, \$6 million on 3 December 2015 and \$4.5 million on 28 July 2016. During 2018, the Group made principal repayments of \$1.5 million.

Since inception the Group has funded its operations primarily through the issuance of equity securities and debt funding. The Group continues to explore funding strategies (e.g., equity, debt, partnering) to support its activities into the future, including the possibility of a listing on NASDAQ or other US stock exchange and a related public or other offer of securities.

Principal risks and uncertainties

The principal risks and uncertainties faced by the Group and/or its industry for the remaining six months of 2018 remain substantially unchanged from the risks disclosed in the Prospectus, which is available on our website.

A summary of the principal risks relating to the Company and/or its industry include the following:

- We have incurred significant operating losses and may not be able to achieve or subsequently maintain profitability.
- We expect to require additional funds in the future in order to meet our capital and expenditure needs and further financing may not be available when required or, if available, could require us to agree to terms which are specifically favourable to new investors, or to restrictions significantly limiting our access to additional capital.
- Our future financial performance is entirely dependent on the commercial success of ReActiv8, our only product as of the date of this Report, obtaining adequate reimbursement for ReActiv8, and rates of product adoption and market penetration.
- Failure to comply with debt covenants or failure to make repayments on our debt facility could have a material adverse effect.
- We operate in a highly regulated environment and regulatory approval is required before we can market or sell ReActiv8 in any market.
- Seeking and obtaining regulatory approval for medical devices can be a long and uncertain process. Strict or changing regulatory regimes, government policies and legislation in any of our target markets may delay, prohibit or reduce potential sales.
- We are required to conduct clinical trials for regulatory approvals and other purposes. Clinical trials carry substantial risks and are costly and time consuming, with uncertain results.
- Any inability to fully protect and exploit our intellectual property may adversely impact our financial condition, business, prospects and results of operations.

A more extensive description of the existing and future potential risks to Mainstay's business and to the Company's ordinary shares are outlined in the Risk Factors section of the Prospectus, on pages 4 to 25, and should be considered carefully by shareholders and prospective investors.

Outlook and future developments

During the first half of 2018, significant further progress was made in Mainstay's pivotal IDE Clinical Trial, ReActiv8-B, which is intended to gather data in support of a pre-market approval (PMA) application to the FDA, a key step towards the commercialization of ReActiv8 in the US. Completion of all implants was announced at the start of the third quarter of 2018. The completion of implants in the Trial means the Company remains on track to announce full data towards the end of 2018.

If successful, the ReActiv8-B Clinical Trial will yield data in support of an application for pre-market approval (PMA) from the FDA. The data will also comprise Level 1 Evidence of efficacy, which may be used to support applications for favorable reimbursement in the US. Data from the ReActiv8-B Trial will also be used to support market development activities worldwide.

Our refined commercialization strategy and repositioned commercial team is gaining traction. Our strategy is to focus on adoption in a select number of high volume spine care centers to develop key reference sites, and then build on that experience and data from the ReActiv8-B Trial to expand commercialization to additional centers and other countries.

Related party transactions

Refer to note 12.

Going concern

The Directors have evaluated whether there are conditions and events, considered in aggregate, that raise doubt about the Group's ability to continue as a going concern within one year of the date of issue of the consolidated financial statements. The Directors note the following relevant matters:

- The Group had cash of \$29.7 million as at 30 June 2018 (\$10 million as at 31 December 2017).
- The Group had operating cash out-flows of \$14.8 million for the 6 months ended 30 June 2018 (year ended 31 December 2017: \$24.9 million).
- Due to the phase of development of the Group, the Group expects to continue to incur losses in the medium term due to the ongoing investment in research and development, clinical and commercial activities.
- The Group has an accumulated retained loss reserve of \$142.5 million and a reorganization reserve of \$44.6 million as at 30 June 2018 (31 December 2017: \$124.5 million and \$44.6 million, respectively).
- The Group has funded operations to date through the proceeds of equity funding of approximately \$123.5 million and as at 30 June 2018, debt with an outstanding principal of \$11.7 million.

In the event that additional funding is not secured in the 12 months from the approval of these Financial Statements, the Directors believe that the Group has the ability, based on its currently available cash resources, to consider alternative budgets to manage its cash outflows so as to match those available cash resources, to ensure that the Group will have sufficient funds to be able to meet its liabilities as they fall due for a period of at least 12 months from the date of the Financial Statements. On that basis the Directors are satisfied that there is no substantial doubt about the Group's ability to continue as a going concern and that the Financial Statements should be prepared on a going concern basis.

Auditors

The condensed consolidated Financial Statements have not been reviewed by the Company's auditors.

Mainstay Medical International plc Directors' responsibilities statement

Statement of the Directors in respect of Half Year Financial Report

Each of the Directors of the Company (the Directors), whose names and functions are listed in the Corporate and Shareholder Information, confirm that, to the best of each person's knowledge and belief:

- (a) the condensed consolidated Financial Statements comprising the condensed consolidated statement of profit or loss and other comprehensive income, the condensed consolidated statement of financial position, the condensed consolidated statement of changes in equity, the condensed consolidated statement of cash flows and related notes 1 to 13 have been prepared in accordance with IAS 34 *Interim Financial Reporting* as adopted by the EU.
- (b) the interim management report includes a fair review of the information required by:
 - a. *Regulation 8(2) of the Transparency (Directive 2004/109/EC) Regulations 2007*, being an indication of important events that have occurred during the first six months of the financial year and their impact on the condensed consolidated Financial Statements; and a description of the principal risks and uncertainties for the remaining six months of the year; and
 - b. *Regulation 8(3) of the Transparency (Directive 2004/109/EC) Regulations 2007*, being related party transactions that have taken place in the first six months of the current financial year and that have materially affected the financial position or performance of the entity during that period; and any changes in the related party transactions described in the last annual report that could do so.

On behalf of the Board on 19 September 2018,

Oern Stuge MD
Chairman

Jason Hannon
CEO

Mainstay Medical International plc
Condensed consolidated statement of profit or loss and other comprehensive income
for the half year ended 30 June 2018

(\$'000)	Notes	Half year ended 30 June 2018 Unaudited	Half year ended 30 June 2017 Unaudited
Revenue	4	358	250
Cost of sales		<u>(170)</u>	<u>(136)</u>
Gross profit		188	114
Operating expenses		<u>(15,849)</u>	<u>(12,282)</u>
Operating loss		<u>(15,661)</u>	<u>(12,168)</u>
Finance income		-	10
Finance expense		<u>(1,018)</u>	<u>(986)</u>
Net finance expense		<u>(1,018)</u>	<u>(976)</u>
Loss before income taxes		(16,679)	(13,144)
Income taxes	6	<u>156</u>	<u>(131)</u>
Loss for the half year		<u>(16,523)</u>	<u>(13,275)</u>
Net loss attributable to equity holders		(16,523)	(13,275)
Basic and diluted loss per share (in \$)	5	<u>(2.01)</u>	<u>(2.01)</u>
Other Comprehensive Income			
<i>Items that are or may be reclassified subsequently to the statement of profit or loss:</i>			
Foreign currency translation differences of foreign operations		<u>56</u>	<u>(50)</u>
Total comprehensive loss for the half year		<u>(16,467)</u>	<u>(13,325)</u>
Total comprehensive loss attributable to equity holders		<u>(16,467)</u>	<u>(13,325)</u>

The accompanying notes form an integral part of these condensed consolidated interim Financial Statements.

Mainstay Medical International plc
Condensed consolidated statement of financial position
at 30 June 2018

(\$'000)	Notes	30 June 2018 Unaudited	31 December 2017 Audited
Non-current assets			
Property, plant and equipment		177	201
Current assets			
Inventory		2,474	2,395
Trade and other receivables		875	571
Income tax receivable		345	205
Cash and cash equivalents		29,711	9,975
Total current assets		33,405	13,146
Total assets		33,582	13,347
Equity			
Share capital	8	67	64
Share premium		143,897	106,414
Other reserves		4,649	4,593
Share based payment reserve		9,465	7,613
Retained loss		(142,468)	(124,505)
Surplus/ (deficit) on shareholders' equity		15,610	(5,821)
Non-current liabilities			
Loans and borrowings	7	9,991	11,177
Total non-current liabilities		9,991	11,177
Current liabilities			
Loans and borrowings	7	3,182	3,214
Income tax payable		12	124
Trade and other payables		4,787	4,653
Total current liabilities		7,981	7,991
Total liabilities		17,972	19,168
Total equity and liabilities		33,582	13,347

The accompanying notes form an integral part of these condensed consolidated interim Financial Statements.

Mainstay Medical International plc
Condensed consolidated statement of changes in shareholders' equity
for the half year ended 30 June 2018

(\$'000)	Share capital	Share premium	Other reserves	Share based payment reserve	Retained loss	Total equity
Balance as at 1 January 2017	64	106,360	4,735	4,606	(94,707)	21,058
<i>Loss for the half year</i>	-	-	-	-	(13,275)	(13,275)
<i>Other comprehensive income for the half year</i>	-	-	(50)	-	-	(50)
Total comprehensive loss for the half year	-	-	(50)	-	(13,275)	(13,325)
<i>Transactions with owners of the Company:</i>						
Share based payments	-	-	-	1,296	-	1,296
Issue of shares on exercise of share options or warrants	-	4	-	(3)	3	4
Balance at 30 June 2017 (Unaudited)	64	106,364	4,685	5,899	(107,979)	9,033
<i>Loss for the half year</i>	-	-	-	-	(16,560)	(16,560)
<i>Other comprehensive income</i>	-	-	(92)	-	-	(92)
Total comprehensive loss for the half year	-	-	(92)	-	(16,560)	(16,652)
<i>Transactions with owners of the Company:</i>						
Share based payments	-	-	-	1,748	-	1,748
Issue of shares on exercise of share options or warrants	-	50	-	(34)	34	50
Balance at 31 December 2017	64	106,414	4,593	7,613	(124,505)	(5,821)
<i>Loss for the half year</i>	-	-	-	-	(16,523)	(16,523)
<i>Other comprehensive income for the half year</i>	-	-	56	-	-	56
Total comprehensive loss for the half year	-	-	56	-	(16,523)	(16,467)
<i>Transactions with owners of the Company:</i>						
Share based payments	-	-	-	1,852	-	1,852
Issue of shares	3	37,483	-	-	(1,440)	36,046
Balance at 30 June 2018 (Unaudited)	67	143,897	4,649	9,465	(142,468)	15,610

The accompanying notes form an integral part of these condensed consolidated interim Financial Statements.

Mainstay Medical International plc
Condensed consolidated statement of cash flows
for the half year ended 30 June 2018

(\$'000)	Notes	Half year ended 30 June 2018 Unaudited	Half year ended 30 June 2017 Unaudited
Cash flow from operating activities			
Net loss for the half year		(16,523)	(13,275)
Add/(less) non-cash items			
Depreciation		50	52
Finance income		-	(10)
Finance expense		1,018	986
Share-based compensation	10	1,852	1,296
Income taxes	6	(156)	131
Add/(less) changes in working capital			
Trade and other receivables		(306)	12
Inventory		(80)	(831)
Trade and other payables		76	1,143
Taxes paid		(112)	(238)
Interest paid		(603)	(656)
Net cash used in operations		(14,784)	(11,390)
Cash flow from investing activities			
Acquisition of property and equipment		(26)	(35)
Net cash used in investing activities		(26)	(35)
Cash flow from financing activities			
Gross proceeds from issue of shares		37,486	4
Transaction costs on issue of shares		(1,440)	-
Repayment of borrowings	7	(1,500)	(750)
Net cash inflow/(outflow) from financing activities		34,546	(746)
Net increase/(decrease) in cash and cash equivalents			
		19,736	(12,171)
Cash and cash equivalents at beginning of year		9,975	36,670
Cash and cash equivalents at 30 June 2018		29,711	24,499

The accompanying notes form an integral part of these condensed consolidated interim Financial Statements.

Mainstay Medical International plc

Notes to the condensed consolidated Financial Statements

1 General information and reporting entity

Mainstay Medical International plc (the Company) is a company incorporated and registered in Ireland. Details of the registered office, the officers and advisers to the Company are presented on the Corporate and Shareholder Information page.

The Half Year Report and condensed consolidated Financial Statements for the periods ended 30 June 2018 and 30 June 2017 comprise the results of the Company and of its subsidiaries (together the Group).

At 30 June 2018, the Group comprises the Company and its operating subsidiaries Mainstay Medical Limited, Mainstay Medical Distribution Limited, Mainstay Medical GmbH, Mainstay Medical B.V., MML US, Inc. and Mainstay Medical (Australia) Pty. Limited.

The Company's shares are quoted on Euronext Paris and the ESM of Euronext Dublin.

Mainstay is a medical device company focused on developing and commercializing ReActiv8®, an implantable restorative neurostimulation system designed to treat an underlying cause of disabling Chronic Low Back Pain (CLBP).

2 Basis of preparation

Statement of compliance

The condensed consolidated Financial Statements have been prepared in accordance with IAS 34 Interim Financial Reporting as adopted by the EU. They do not include all the information and disclosures necessary for a complete set of IFRS Financial Statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance since the last annual consolidated financial statements as at and for the year ended 31 December 2017.

The comparative information provided in the condensed consolidated Financial Statements relating to the periods ended 30 June 2017 and 31 December 2017 does not comprise the statutory financial statements of the Group. Those statutory financial statements for the year ended 31 December 2017 on which the auditors gave an unqualified audit opinion, have been delivered to the Companies Registry Office.

There are no significant or material changes to judgements or estimates used in these condensed consolidated Financial Statements compared with those used in the consolidated Financial Statements for the year ended 31 December 2017.

The condensed consolidated Financial Statements were authorized for issue by the Board of Directors, on 19 September 2018.

Going concern

The Directors have evaluated whether there are conditions and events, considered in aggregate, that raise doubt about the Group's ability to continue as a going concern within one year of the date of issue of the consolidated financial statements. The Directors note the following relevant matters:

- The Group had cash of \$29.7 million as at 30 June 2018 (\$10 million as at 31 December 2017).
- The Group had operating cash out-flows of \$14.8 million for the 6 months ended 30 June 2018 (year ended 31 December 2017: \$24.9 million).
- Due to the phase of development of the Group, the Group expects to continue to incur losses in the medium term due to the ongoing investment in research and development, clinical and commercial activities.
- The Group has an accumulated retained loss reserve of \$142.5 million and a reorganization reserve of \$44.6 million as at 30 June 2018 (31 December 2017: \$124.5 million and \$44.6 million, respectively).
- The Group has funded operations to date through the proceeds of equity funding of approximately \$123.5 million and as at 30 June 2018, debt with an outstanding principal of \$11.7 million.

In the event that additional funding is not secured in the 12 months from the approval of these Financial Statements, the Directors believe that the Group has the ability, based on its currently available cash resources, to consider alternative budgets to manage its cash outflows so as to match those available cash resources, to ensure that the Group will have sufficient funds to be able to meet its liabilities as they fall due for a period of at least 12 months from the date of the Financial Statements. On that basis the Directors are satisfied that there is no substantial doubt about the Group's ability to continue as a going concern and that the Financial Statements should be prepared on a going concern basis.

Currency

The condensed consolidated Financial Statements are presented in US Dollars (\$), which is the functional and presentational currency of the Company. Balances in the condensed consolidated Financial Statements are rounded to the nearest thousand (\$'000) except where otherwise indicated.

Basis of consolidation

The condensed consolidated Financial Statements comprise the consolidated results of Mainstay Medical International plc and its subsidiaries.

Significant accounting policies

With the exception of the newly implemented policies noted below, the condensed consolidated Financial Statements have been prepared applying the accounting policies that were applied in the preparation of the Group's consolidated Financial Statements for the year ended 31 December 2017, which were prepared in accordance with IFRS and are available on the Company's website (www.mainstay-medical.com) except as detailed below. These accounting policies have been applied consistently for all periods presented.

The Group has initially adopted IFRS 15 Revenue from Contracts with Customers and IFRS 9 Financial Instruments from 1 January 2018. The implementation of these standards had no material impact on the Group's reported results.

a) Revenue recognition

The Group has initially adopted IFRS 15 Revenue from Contracts with Customers from 1 January 2018. Under IFRS 15, revenue is measured based on the consideration specified in a contract with a customer. The Group recognises revenue when it transfers control over a product or service to a customer. This may arise on shipment, delivery or in accordance with specific terms and conditions agreed with customers and provided there are no material remaining performance obligations required of the Group.

Revenue is measured at the fair consideration received/receivable for the sale of goods to external customers net of value added tax and discounts. Expected discounts are estimated and provided for as a reduction in revenue based on agreements with customers, agreed promotional arrangements and accumulated experience. Accumulated experience is used to estimate and provide for the discounts, using the expected value method, and revenue is only recognised to the extent that it can be reliably measured and when it is probable that future economic benefits of the transaction will flow to the Group. Service revenues (relating to training and implant support) are recognized when the related services are rendered. When a customer is invoiced, or cash is received but conditions for recognition of the related revenues have not been met, revenue is deferred until all conditions are met. The Group occasionally sells goods and services as a bundled arrangement. Such sales are unbundled based on the relative fair value of the individual goods and services components and each component is recognized separately in accordance with the Group's recognition policy.

Due to the stage of development of the Group, and the nature of the Group's current activities (the Group has only one product, ReActiv8, and some related accessories and services available for sale), this new standard has not had a material impact on the Group and there has been no restatement of previously reported amounts.

b) Financial Instruments

The change in accounting policy to comply with the requirements of IFRS 9 has had no impact on the amounts disclosed in the financial statements other than immaterial changes to impairment of trade and other receivables as discussed below. The changes in classification of financial assets and liabilities to IFRS 9 classification has had no impact on the accounting for those assets and liabilities.

Classification and measurement of financial assets and liabilities

On initial recognition a financial asset is classified as Measured at Amortised Cost, FVOCI or FVTPL. Financial assets are not reclassified after initial recognition unless the related business model changes. A financial asset is measured at amortised cost if it is held in a business model whose objective is to hold assets to collect contractual cashflows and its contractual terms give rise on specific dates to cash flows that are solely payments of principal or interest.

Trade and other receivables

Trade and other receivables are classified by the Group as amortised cost assets under IFRS 9. These assets are recognised initially at fair value. Subsequent to initial recognition, they are measured at amortised cost using the effective interest method, less any impairment losses.

Cash and cash equivalents

Cash and cash equivalents are classified by the Group as amortised cost assets under IFRS 9. Cash and cash equivalents comprise cash balances and call deposits with maturities of three months or less, which are carried at amortised cost.

Trade and other payables

Trade and other payables are classified by the Group as other financial liabilities under IFRS 9. These liabilities recognised initially at fair value. Subsequent to initial recognition, they are measured at amortised cost using the effective interest method.

Interest-bearing borrowings

Interest-bearing borrowings are classified by the Group as other financial liabilities under IFRS 9 and are recognised initially at fair value including any attributable transaction costs. Subsequent to initial recognition, interest-bearing borrowings are stated at amortised cost using the effective interest method over the contractual term.

Trade and other receivables and cash and cash equivalents were previously classified as loans and receivables under IAS 39. There has been no change in the classification of trade and other payables or interest-bearing borrowings.

Impairment of financial assets

At each reporting date, in accordance with IFRS 9, the Group assesses whether its financial assets, comprising of accounts receivable and cash are impaired. The Group evaluates customer accounts with past-due outstanding balances, and analyses customer credit worthiness, payment patterns and trends. Based upon a review of these accounts and management's analysis and judgement, we estimate the future cash flows expected to be recovered from these receivables. As at 30 June 2018, our trade and other receivables balances amounted to \$16,000, and we have not recognized any material impairment losses at this time. The total outstanding balance as at 30 June 2018 was received post period end. Further information on the Group's credit risk is detailed in Note 9. The Company measures loss allowances at an amount equal to lifetime expected credit losses, except for cash which is measured at 12-month expected credit losses. The maximum period considered when estimating expected credit losses is the maximum contractual period of exposure to credit risk.

c) Other new standards and interpretations

In addition, the Group applied the standards listed below for the first time in the current period:

- IFRS 2 (amended) - Share Based Payments (effective 1 January 2018)
- Annual Improvements to IFRSs 2014 – 2016 Cycle: Amendments to IFRS 1 First time Adoption of IFRSs and IAS 28 Investment in Associates and Joint Ventures (IASB effective date 1 January 2018, not yet endorsed by the EU)
- Transfers of Investment Property (Amendments to IAS 40) (effective 1 January 2018)

None of these have had any material impact on the Group's implementation of accounting policies or on its reported results.

3 Segment reporting

Due to the nature of the Group's current activities, the Group considers there to be one operating segment, Active Implantable Medical Devices (AIMDs). The results of the Group are reported on a consolidated basis to the Chief Operating Decision Maker of the Group, the Chief Executive Officer. There are no reconciling items between the Group's reported consolidated statement of profit or loss and other comprehensive income and statement of financial position and the results of the AIMDs segment.

The Group has operations in Europe, the US and Australia. The non-current assets held in these jurisdictions are detailed below:

(\$'000)	30 June 2018	31 December 2017
Ireland	30	47
Germany	3	5
United States	144	149
Total non-current assets	177	201

The Group's total revenue by country is detailed below:

(\$'000)	Half year ended 30 June 2018	Half year ended 30 June 2017
Germany	250	231
Ireland	90	19
Other Europe	18	-
Total revenue by country	358	250

4 Revenue

(\$'000)	Half year ended 30 June 2018	Half year ended 30 June 2017
Revenue arising from the sale of goods	358	250
	358	250

5 Earnings per share

As the Group is incurring operating losses, there is no difference between basic and diluted earnings per share.

	Half year ended 30 June 2018	Half year ended 30 June 2017
Weighted average number of ordinary shares in issue	8,235,367	6,612,012
Loss per share	2.01	2.01

6 Taxes

Current income tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid to the relevant taxation authorities. The tax charge has been prepared based on the Group's best estimate of the weighted average tax rate that is expected for the full financial year. The tax rates and tax laws used to compute the amount are those used in Ireland, Germany, the Netherlands, the United States and Australia.

7 Interest bearing loans and borrowings

IPF Debt Financing

The Group's debt facility is secured by way of fixed and floating charges over the assets and undertakings of Mainstay Medical Limited, and the Mortgage Debenture includes customary terms and conditions. In addition, Mainstay Medical International plc has created a first fixed charge in favor of IPF over its present and future shares held in Mainstay Medical Limited.

The terms of the agreement include a requirement that Mainstay Medical Limited hold a minimum cash balance of \$2 million or achieve revenue targets within an agreed timeframe. The Group is not in breach of any covenants at 30 June 2018 and has not been in breach at any reporting date.

(\$'000)	30 June 2018	31 December 2017
<i>Loans and borrowings - current</i>		
Term loan	3,000	3,000
Deferred finance cost	(90)	(90)
Accrued interest	272	304
Total current loans and borrowings	3,182	3,214
<i>Loans and borrowings – non-current</i>		
Term loan	8,700	10,200
Deferred finance cost	(149)	(194)
Accrued interest	1,440	1,171
Total non-current loans and borrowings	9,991	11,177
Total loans and borrowings	13,173	14,391

8 Called up share capital

The Company's ordinary shares are quoted in Euro and have been translated in US Dollars at the rates prevailing at the date of issue.

Authorized and Issued Share Capital

	30 June 2018	31 December
	€	2017
		€
Authorized		
20,000,000 ordinary shares of €0.001 each	20,000	20,000
40,000 deferred shares of €1.00 each	40,000	40,000
	<u>60,000</u>	<u>60,000</u>
	2018	2017
	\$	\$
Issued, called up and fully paid		
8,770,229 (31 December 2017: 6,618,897) ordinary shares of €0.001 each	11,240	8,562
40,000 deferred shares of €1.00 each	55,268	55,268
	<u>66,508</u>	<u>63,830</u>
In \$'000	<u>67</u>	<u>64</u>

On 15 February 2018, Mainstay raised gross proceeds of €30.1 million (approximately \$37.5 million) through a placement of 2,151,332 new ordinary shares. This issuance of new ordinary shares was recorded in the Statement of Financial Position in USD at the rate on the date of the transaction. Transaction costs directly attributable to the issue of the new ordinary shares of approximately \$1.4 million have been offset against retained earnings (in accordance with the Companies Act 2014).

9 Financial instruments

Financial risk management

In terms of financial risks, the Group has exposure to credit and financial risk, liquidity risk and market risk (comprising foreign currency risk and interest rate risk). This note presents information about the Group's exposure to each of the above risks together with the Group's objectives, policies and processes for measuring and managing those risks.

Risk management framework

Mainstay's Board of Directors has overall responsibility for the establishment and oversight of the Group's risk management framework. The Group's risk management policies are established to identify and analyze the risks faced by the Group, to set appropriate risk limits and controls and to monitor risks and adherence to the limits. Risk management systems and policies will be reviewed regularly as the Group expands its activities and resource base to take account of changing conditions.

The Group has no significant concentrations of financial risk other than concentration of cash with individual banks. The Group is also exposed to credit risk arising on trade receivables, with further information provided under credit risk below. There has been no other significant change during the half year or since the end of the half year to the types or quantum of financial risks faced by the Group or the Group's approach to the management of those risks.

Credit and financial risk

Credit risk is the risk of financial loss to the Group if a customer or counterparty to a financial instrument fails to meet contractual obligations and arises principally from the Group's cash and cash equivalents and trade and other receivables. Credit risk is managed on a Group basis. The maximum exposure to

credit risk is represented by the carrying amount of each asset. The carrying value of receivables is a reasonable approximation of fair value.

Trade receivables comprise of amounts due from customers, all of which were current at 30 June 2018 and 31 December 2017. The Company does not have exposure to significantly different categories of customer and accordingly details of credit risk by customer type or jurisdictions is not provided.

There were no material impairment losses recorded in the period and the provision for expected credit losses at 30 June 2018 is also immaterial. The carrying value of trade receivables of \$16,000 at 30 June 2018 (\$90,000 at 31 December 2017) represents the maximum exposure to credit risk. The Group maintained its cash balances with its principal financial institutions throughout the year, and the Group limits its exposure to any one financial institution by holding cash balances across several financial institutions. The Group's principal financial institutions have investment grade ratings at 30 June 2018. The credit rating status of the Group's principal financial institutions is reviewed by the Audit Committee or the Board annually. The cash balance is reported to the Board of Directors on a monthly basis, and a monthly review of all cash balances held at each institution is carried out by the CFO. The Group maintains most of its cash in USD denominated accounts. The Group held cash and cash equivalents of \$29.7 million as at 30 June 2018.

Liquidity risk

Liquidity risk is the risk that the Group will not be able to meet its financial obligations as they fall due. Since inception the Group has funded its operations primarily through the issuance of equity securities and debt funding. The Group continues to explore funding strategies (e.g., equity, debt, partnering) to support its activities into the future, including the possibility of a listing on NASDAQ or other US stock exchange and a related public or other offer of securities. Adequate additional financing may not be available on acceptable terms, or at all. The Group's inability to raise capital as and when needed would have a negative impact on the Group's financial position and its ability to pursue its business strategy.

Foreign currency risk

The Group's reporting currency is the US Dollar. The Group's exposure to foreign currency risk arises through expenditures incurred in Euros, Great British Pounds (GBP) and Australian Dollars.

The Group's Australian subsidiary has an Australian Dollar functional currency and three of the Group's subsidiaries located in Ireland, Germany and the Netherlands have a Euro functional currency. Additionally, GBP expenditure is mainly incurred from the UK based sites relating to the ReActiv8-A Post Market Clinical Follow-Up ("PMCF") Study and U.S. Pivotal ReActiv8-B Clinical Trial.

The Group did not have material asset or liability amounts in foreign currencies at 30 June 2018 other than trade payables and accruals (net of cash) of €1.2 million and £321,000.

Interest rate risk

The Group's cash balances are maintained in short term access accounts and carry a floating rate of interest. A 50 basis points change in the rate of interest applied to the cash balance held by the Group would not have had a material impact on the Group's statement of profit or loss in the half year ended.

At 30 June 2018, the principal outstanding on MML's loan from IPF was \$11,700,000. This loan carries a variable rate of 3-month Euribor plus a margin ranging from 10.5% to 12.5%.

10 Share based payments

Share Options

The terms and conditions of the Group's share option plan are disclosed in the 2017 Annual Report. The charge of \$1.9 million for the half year ended 30 June 2018 (30 June 2017: \$1.3 million) is the grant date fair value of various share options granted in the current and prior years, which are being recognized within the statement of profit or loss and other comprehensive income over the vesting period related to service. 279,878 options were granted in the six months ended 30 June 2018 (30 June 2017: 30,000 options).

11 Contingencies

The Directors and management are not aware of any contingencies that may have a significant impact on the financial position of the Group.

12 Related party transactions

There were no balances due to or from related parties as at 30 June 2018 and 30 June 2017.

Key management compensation and Directors' remuneration

The Group defines key management as its non-executive directors, executive directors and senior management. Details of remuneration for key management personnel for the six-month reporting period are provided below:

(\$'000)	30 June 2018	30 June 2017
Salaries	817	876
Non-executive directors' fees	135	111
Other remuneration	915	595
Payroll taxes	92	102
Share based payments	1,825	931
Pension	14	11
Total remuneration	3,798	2,626

13 Events subsequent to 30 June 2018

There were no events subsequent to the half year ended 30 June 2018 that would have a material impact on the condensed consolidated interim Financial Statements.